Are adrenergic receptor blockers effective or contraindicated in pulmonary arterial hypertension?

Circulation Journal

Volumn 73, Issue 12, 2009, Pages 2212-2213

  Nakamura, Kazufumi ^a   Fujio, Hideki ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b SUWA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; AROTINOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUNAZOSIN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; ENDOTHELIN RECEPTOR ANTAGONIST; METOPROLOL; NORADRENALIN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN;

CELL PROLIFERATION; DRUG CONTRAINDICATION; DRUG EFFICACY; EDITORIAL; EXERCISE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART RATE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG VASCULAR RESISTANCE; NONHUMAN; PROGNOSIS; PULMONARY HYPERTENSION; SYMPATHETIC NERVE; VASCULAR SMOOTH MUSCLE;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; DISEASE PROGRESSION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; PROPANOLAMINES; RISK ASSESSMENT; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 73349099994     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0807     Document Type: Editorial

References (15)

1. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84.
2. Sakuma M, Demachi J, Nawata J, Suzuki J, Takahashi T, Matsubara H, et al. Epoprostenol infusion therapy changes angiographic findings of pulmonary arteries in patients with idiopathic pulmonary arterial hypertension. Circ J 2008; 72: 1147-1151.
3. Akagi S, Matsubara H, Miyaji K, Ikeda E, Dan K, Tokunaga N, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008; 72: 1142-1146.
4. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
5. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426-2435.
6. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
7. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105: 2867-2871.
8. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004; 110: 1308-1312.
9. Usui S, Yao A, Hatano M, Kohmoto O, Takahashi T, Nagai R, et al. Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. Circ J 2006; 70: 1208-1215.
10. Krowka MJ. Evolving dilemmas and management of portopulmonary hypertension. Semin Liver Dis 2006; 26: 265-272.
11. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: Cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009; 135: 794-804.
12. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
13. Fujio H, Nakamura K, Matsubara H, Kusano KF, Miyaji K, Nagase S, et al. Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 2006; 47: 250-255.
14. Inoue M, Watanabe K, Mori C, Tanaka O. The effect of bunazosin on monocrotaline-induced pulmonary hypertension in rats. Acta Paediatr Jpn 1994; 36: 133-138.
15. Ishikawa M, Sato N, Asai K, Takano T, Mizuno K. Effects of a pure α/β-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. Circ J 2009; 73: 2337-2341.